3/12
07:03 pm
axsm
Axsome Therapeutics Highlights Auvelity's $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference [Yahoo! Finance]
Low
Report
Axsome Therapeutics Highlights Auvelity's $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference [Yahoo! Finance]
3/12
10:26 am
axsm
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)
Low
Report
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)
3/10
07:43 pm
axsm
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Medium
Report
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/10
02:34 pm
axsm
A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth [Yahoo! Finance]
Low
Report
A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth [Yahoo! Finance]
3/10
01:46 pm
axsm
2 Under-the-Radar Stocks to Buy and Hold [Yahoo! Finance]
Low
Report
2 Under-the-Radar Stocks to Buy and Hold [Yahoo! Finance]
3/10
06:40 am
axsm
Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates [Yahoo! Finance]
Low
Report
Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates [Yahoo! Finance]
3/5
11:21 pm
axsm
Axsome Therapeutics touts AUVELITY $155M quarter, doubles salesforce ahead of April FDA decision [Yahoo! Finance]
Low
Report
Axsome Therapeutics touts AUVELITY $155M quarter, doubles salesforce ahead of April FDA decision [Yahoo! Finance]
2/28
01:11 pm
axsm
Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory [Yahoo! Finance]
Low
Report
Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory [Yahoo! Finance]
2/25
09:26 pm
axsm
Axsome Therapeutics Highlights Auvelity Momentum, 600-Rep Sales Push, and April 30 ADA PDUFA at Oppenheimer Conf. [Yahoo! Finance]
Low
Report
Axsome Therapeutics Highlights Auvelity Momentum, 600-Rep Sales Push, and April 30 ADA PDUFA at Oppenheimer Conf. [Yahoo! Finance]
2/25
07:00 am
axsm
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Axsome Therapeutics to Participate in Upcoming Investor Conferences
2/25
06:24 am
axsm
Axsome Therapeutics (AXSM) was upgraded by Wolfe Research to "strong-buy".
Medium
Report
Axsome Therapeutics (AXSM) was upgraded by Wolfe Research to "strong-buy".
2/24
10:04 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
2/24
10:03 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $207.00 price target on by analysts at Morgan Stanley.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $207.00 price target on by analysts at Morgan Stanley.
2/24
09:11 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
2/24
07:18 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
2/24
07:01 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Guggenheim.
2/24
07:00 am
axsm
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
Medium
Report
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
2/23
06:01 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
2/23
03:59 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $200.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $200.00 price target on by analysts at Truist Financial Corporation.
2/23
03:59 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $215.00 price target on by analysts at Jefferies Financial Group Inc..
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $215.00 price target on by analysts at Jefferies Financial Group Inc..
2/23
02:03 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/23
12:54 pm
axsm
Axsome Therapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Axsome Therapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/23
11:22 am
axsm
Why The Axsome Therapeutics (AXSM) Story Is Shifting As Analysts Rework Valuation Models [Yahoo! Finance]
Low
Report
Why The Axsome Therapeutics (AXSM) Story Is Shifting As Analysts Rework Valuation Models [Yahoo! Finance]
2/23
08:37 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $225.00 price target on the stock.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $225.00 price target on the stock.
2/23
07:00 am
axsm
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update